Moderna stock jumps 177% following cancer vaccine results, then drops 20% in a single day

The Phase 2 clinical trial results of Moderna and Merck's mRNA cancer vaccine caused a major shockwave in the biotechnology sector on August 19, as the vaccine demonstrated a 49% reduction in the risk of melanoma recurrence or death compared to Keytruda alone, pushing MRNA stock to surge over 177% in a single trading session.

The surge came amid a heavy buying wave not seen in the biotech sector for years, as investors viewed the announcement as confirmation that mRNA technology—which gained global prominence with COVID vaccines—is proving its ability to reshape the cancer treatment landscape. However, the stock dropped 20% the following day as investors moved to take profits.

Analysts believe this event reprices the technology's probability of success across multiple cancer treatment platforms, not just for Moderna, but for its competitors as well. While some express caution regarding Phase 2 results that might not be replicated in advanced trials, others believe the findings fundamentally and permanently revalue the company.

This announcement positions the mRNA cancer vaccine as the sector's most significant catalyst in recent years, kicking off a race among major companies to leverage this window in other cancer types. The irony is that a technology born to fight a virus could become the most effective weapon in the war on cancer since the discovery of chemotherapy.

What do these terms mean?

mRNA Cancer Vaccine: A personalized vaccine that teaches the immune system to recognize and destroy specific cancer cells, designed for each patient based on the unique characteristics of their tumor—like updating a defense software customized for each device.

Melanoma: The most dangerous type of skin cancer, originating in the pigment-producing cells responsible for skin color—treatment prospects in advanced stages were limited before the emergence of modern immunotherapies.

Phase 2b Clinical Trials: An intermediate stage testing the efficacy of a vaccine or drug on a larger group of patients—its success is a strong signal, but it does not guarantee final approval prior to completing advanced stages.